Enhancing surveillance of sexually transmitted infections in England with gender identity and behavioural data: the GUMCAD STI Surveillance System

Hamish Mohammed[1*], Stephanie J. Migchelsen[1], Stephen Duffell[1], Ana Karina Harb[1], Tika Ram[1], John Were[1], Sheel Patel[2], Monty Moncrieff[3], James Hardie[2], Maryam Shahmanesh[4], David Phillips[5], Sonali Wayal[4,6], Anthony Nardone[1], Ann Sullivan[2], Claudia Estcourt[7], Jackie A. Cassell[1,8,9], Gwenda Hughes[10], Katy Sinka[1]

Affiliations:

1. UK Health Security Agency
2. Chelsea and Westminster Hospital NHS Foundation Trust
3. London Friend
4. University College London
5. Croydon University Hospital NHS Trust
6. Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University
7. Glasgow Caledonian University
8. Brighton and Sussex Medical School
9. University of Kent
10. London School of Hygiene and Tropical Medicine

* *Corresponding author:*
Dr. Hamish Mohammed
Consultant STI Surveillance & Prevention Scientist (and Honorary Associate Professor, University College London)
Blood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, 61 Colindale Avenue, London, UK NW9 5EQ
hamish.mohammed@ukhsa.gov.uk

Conflict of interest statement

AN was a member of the Steering Group for the pilots of the enhanced GUMCAD specification while he was an employee of Public Health England (PHE; the predecessor to the UK Health Security Agency [UKHSA]); he is now an employee of EpiConcept, a privately funded company. JW conducted analyses of the data collected from the pilots (the results of which are presented in the Appendix) while he was an employee of PHE; he is now an employee of Parexel International Limited, a privately funded clinical research organisation. None of the other coauthors reported any conflicts of interest.

Funding statement

The first pilot was funded internally by PHE's Innovation Fund.

Abstract

Background

There has been an increasing trend in sexually transmitted infections (STIs) in England since the early 2000s. Since 2008, surveillance of STIs in England has been conducted using GUMCAD, a depersonalised dataset of all attendances at all publicly commissioned sexual health services (SHS).

Aim

This article describes the piloting and rollout of an enhanced specification of GUMCAD at SHS in England.

Methods

GUMCAD was enhanced in 2019 to allow SHS to report the gender identity (whether cisgender, transgender or gender diverse) of service users, as well as selected behavioural information collected during routine sexual history taking such as the number of recent sex partners (last 3 months).

Results

The reporting of GUMCAD data to the UK Health Security Agency (UKHSA) has provided disaggregate data on services provided and STI diagnoses at SHS since 2008. 2023 was the first calendar year over which the majority of SHS (93%, 224/241) submitted enhanced GUMCAD data including sexual behaviours and gender identity to UKHSA.

Conclusions

This enhancement to GUMCAD provides an opportunity to improve the surveillance of STIs, better understand sexual health need, and improve the uptake and targeting of existing and novel preventative interventions for STIs such as 4CMenB vaccination for gonorrhoea and doxycycline post-exposure prophylaxis (doxyPEP) in England.

Main text

Introduction

Sexually transmitted infections (STIs) include a range of bacterial, viral and protozoal infections which are primarily transmitted through sexual contact. STIs can result in acute symptoms such as genital ulcers or discharge, dysuria and testicular or pelvic pain; while many people may not experience any symptoms, if untreated, STIs may result in further onward transmission and adverse sequelae such as ectopic pregnancy, infertility, and neonatal mortality.

In England, there has been an increasing trend in diagnoses of bacterial STIs such as gonorrhoea and syphilis since the early 2000s [1,2]. When compared to heterosexual people, gay, bisexual and other men who have sex with men (GBMSM) have disproportionately higher diagnosis rates of gonorrhoea and syphilis [3]; this may be a result of factors including higher rates of STI testing as well as behaviours such as multiple condomless sex partners [4,5]. Since the cessation of the last national lockdown to control COVID-19 in July 2021, there has been a rapid resurgence in gonorrhoea [6] with larger proportional rises in heterosexuals [7].

Genitourinary medicine, also known as Sexual Health and HIV Medicine, is a medical speciality in the UK which includes the prevention and management of STIs and HIV, care of people living with HIV, and promotion of overall sexual health and wellbeing [9]. England has a national network of open access sexual health services (SHS) with staff trained in genitourinary medicine who perform STI and HIV testing and management, partner notification (PN), and offer preventative interventions such as HIV pre-exposure prophylaxis (PrEP) [8]. Sexual health services are free at the point of delivery and, relative to other primary care settings, diagnose the majority of STIs [9,10].

In 2008, the Health Protection Agency (now the UK Health Security Agency [UKHSA]) worked with sexual healthcare practitioners to develop and introduce a new mandatory national STI surveillance system which collected, for the first time, disaggregated data on attendances, diagnoses made and services provided at all SHS in England using the Genitourinary Medicine Clinic Activity Dataset (now referred to as ‘GUMCAD’) [9]. While GUMCAD has been established as a comprehensive, high-quality STI surveillance system and has been extensively used to inform sexual health policy decisions and evaluate interventions, it was limited by a lack of key information on sexual behaviour and the outcomes of PN. Given the critical role of sexual behaviour and the effectiveness of PN in reducing STI transmission, we introduced an enhancement to the GUMCAD specification

including behavioural and PN variables. Additionally, given evidence of the poorer sexual health of people who are transgender [10], UKHSA also added a variable to GUMCAD to assess gender identity (whether cisgender, transgender or gender diverse). In this article, we describe the piloting and implementation of this enhanced STI surveillance system.

Methods

UKHSA performs surveillance of STIs, including the piloting described in this article, for health protection purposes under permissions granted to UKHSA to collect and process pseudonymised GUMCAD patient data under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2020 and Section 251 of the National Health Service Act 2006. Ethical approval was not required for this analysis.

We conducted a mixed methods iterative pilot of an enhanced GUMCAD surveillance dataset. The legacy GUMCAD specification and its development are described elsewhere [9]. Briefly, GUMCAD is the mandatory surveillance system for STIs in England and is an electronic dataset submitted quarterly to UKHSA by all publicly commissioned SHS since 2008; there were 241 SHS in England registered to report GUMCAD in 2023. SHS, including online services, are commissioned by the 153 upper-tier local authorities (administrative local government bodies) in England. Reporting GUMCAD data to UKHSA for public health surveillance is a mandatory requirement of the Department of Health and Social Care [14]. GUMCAD data are pseudonymised and depersonalised (reported without direct identifiers such as name, date of birth or full address) [15], but have a clinic-specific alphanumeric code (patient ID) that allows follow-up of individuals attending the same service over time. GUMCAD includes demographic information aligned with national data standards [16, 17], as follows: gender, sexual orientation, age, ethnicity, country of birth, and lower super output area of residence [small geographical areas with resident populations between 1,000-3,000 people].

To avoid double counting when reporting the numbers of STI tests or diagnoses, episodes of care are created during data cleaning to ensure, for example, only one diagnosis of chlamydia is retained within a 42-day period. A sensitivity analysis comparing 42-days to shorter episode lengths confirmed that reducing this to 14- or 28-days had a negligible impact on the number of episodes [18].

Development of the enhanced GUMCAD specification

The enhanced GUMCAD specification included behavioural data recommended by the British Association for Sexual Health and HIV (BASHH) for sexual history taking [18] and

audits of PN at SHS [20] (Table 1). The development of the pilot specification was undertaken by a multi-disciplinary steering group of key stakeholders representing sexual health clinicians and health advisors, academia, LGBTQ+ charities, substance use specialists, software suppliers of electronic patient record [EPR] management systems, and UKHSA.

Piloting

We performed two pilots, with the findings from the first pilot used to inform refinements to the dataset specification for the second. For the first pilot, a geographically dispersed convenience sample of SHS serving diverse communities including GBMSM, young adults, and minority ethnic populations was recruited. When selecting SHS for the pilot, we prioritised those using the most commonly used EPR software at SHS in England (at least one SHS in each of the 9 public health regions of England), and contacted them directly to seek their participation. Recruitment of SHS to the first pilot commenced in early 2013, with staggered start dates. The pilot was run for 8-weeks at each SHS and included all service users. Technical guidance on recording each new variable was provided to all pilot SHS and their software providers to standardise data collection. Prior to data collection, UKSHA staff held initiation meetings with participating services to explain the specification and pilot methodology. Each of the pilot SHS' EPR software suppliers was required to make changes to their service's EPR system to facilitate the recording, extraction and uploading of data (as a single comma-separated value file) using the updated GUMCAD specification to the established secure online facility for GUMCAD surveillance reporters to submit data to UKHSA [21]. With the endorsement of the steering group, a second pilot using a revised dataset specification was conducted in 2015/16 in 5 of the 8 SHS which participated in the first pilot.

Assessing the feasibility and acceptability of the enhanced GUMCAD specification

Firstly, we assessed the feasibility and acceptability of the pilot enhancement to service providers (doctors, nurses and health advisers [healthcare practitioners with expertise in PN [22]]) at pilot SHS using self-administered, anonymous online surveys conducted after each of the 2 pilots (Appendix Figure 1), and confidential key informant interviews using a topic guide after the first pilot (Appendix Document 1).

The survey included close-ended questions on the acceptability, ease and potential benefit of collecting additional behavioural data and how easily this could be integrated into routine clinical practice. After the first pilot, respondents indicated their willingness to participate in confidential key informant interviews. The aim was to interview at least one member of staff

at each of the SHS in the first pilot or until thematic saturation was achieved. We transcribed the interviews into anonymised scripts, then performed thematic analysis of coded interview data on the feasibility and acceptability of collecting the enhanced data after the first pilot.

Secondly, we performed a descriptive analysis of the data on service users reported by pilot SHS to assess the representativeness of service users with enhanced GUMCAD data submitted (versus those without), and item non-response (all variables reported with a 'not known' or 'not stated' response) using proportions. As the survey data from service providers and data quality of the data on service users from the second pilot were used to inform the final version of the enhanced GUMCAD specification, we present the results of descriptive analyses of survey responses and data quality indicators (frequencies and proportions) from the second pilot.

The steering group endorsed the final version of the enhanced GUMCAD specification, after which UKHSA sought approval for this specification from NHS England Digital's Data Coordination Board (DCB) as the new mandatory STI surveillance dataset in England. The DCB assessed the burden and feasibility of data collection at SHS, as they do for other publicly provided healthcare settings.

Results

Feedback from the first pilot

Eight SHS participated in the first pilot in 2013/14. These 8 services were dispersed geographically throughout England (the East of England, London, Midlands, Southeast and Southwest; Appendix Table 1). All participating SHS successfully submitted their piloted GUMCAD enhanced data through the UKHSA's secure online facility.

In the first pilot, a total of 4 members of staff from 3 of the participating SHS was interviewed. They all agreed that the proposed questions in the enhanced GUMCAD specification were asked routinely during sexual history taking and would be beneficial to the management of service users and to public health. However, the level of detail in the initially proposed specification in 2013 was considered overly burdensome, beyond the scope of routine practice, and disproportionate relative to the prevalence of certain behaviours, such as chemsex, among all SHS attendees. Despite this, one SHS continued to use that specification after the pilot while others used specific sections such as recreational drug use behaviours after the 8-week pilot period for internal use. The feedback from the first pilot was used to refine the enhanced GUMCAD specification to remove detailed questions about sexualised drug use and some GBMSM-specific sexual behaviours, then a revised specification was used in the second pilot. Revisions to the specification were made by a

consensus among members of the steering group after the review of the qualitative (key informant interviews) data summarised above, and quantitative data on item non-response for the enhanced GUMCAD data from service users (data not shown).

Feedback and data quality from the second pilot

Five of the 8 SHS which participated in the first pilot also participated in the second in 2015/16, all of which submitted these data through the UKHSA's secure online facility. Among the 23,107 records submitted by these 5 SHS over the 8-week pilot period (Appendix Table 1), 94.3% (21,789) matched a record in their routine GUMCAD extract; this ranged from 78.8% to 99.9% among the pilot SHS. The distribution of gender, age-group and ethnicity was similar when comparing records for which enhanced data were submitted to other records (Appendix Figures 2-4).

A total of 21 clinic staff from 4 pilot SHS completed the online survey. Overall, the proposed enhancement to GUMCAD was viewed positively, with 43% of respondents agreeing that the piloted data items were beneficial or consistent with clinical practice for sexual history taking, while the majority (57-71%) agreed that the technical guidance document was clear, and that these data items were easy to collect and acceptable to patients (Appendix Tables 2-3).

Finalising the specification for approval

While the second pilot demonstrated that the proposed enhancement to GUMCAD was feasible to collect and acceptable within routine clinical practice from the perspective of service providers, further refinements were made to the final specification for simplicity and to reduce the burden of data collection before applying for DCB approval. For example, collecting data on whether recent sexual intercourse took place outside the UK was removed due to the difficulties assessing this reliably, while data on past STI diagnoses or HIV testing were removed due to high item non-response (data not shown), but also because this information would be available in GUMCAD for people reattending the same SHS.

To enable the collection of data on gender identity and after input from the steering group, a question to collect data on sex registered at birth was also added to the GUMCAD specification. Gender identity using GUMCAD data is defined using 2 questions: (i) "what is the patient's gender identity?" (female [including transgender women], male [including transgender men], non-binary, other); and (ii) "is the patient's gender identity the same as their sex registered at birth?" (yes, no, not stated). Some additional refinements were made to the GUMCAD specification to account for changes in the delivery of sexual health services taking place at the time – for instance, a new category to monitor testing for STIs or HIV using an online postal self-sampling kit [23] was added to the variable capturing the

modality of accessing an SHS (which had previously only distinguished between face-to-face attendances and telephone consultations). As was the case after the first pilot, the final specification was created by consensus agreement from the steering group.

The DCB granted approval in 2018 [24] and UKHSA commenced rollout in 2019. Following a pause in 2020 during the COVID-19 pandemic, rollout resumed in September 2021. 2023 was the first calendar year over which more than 90% of SHS reported enhanced GUMCAD data to UKHSA.

Findings of relevance to improving care

As of December 2023, all 241 SHS in England submitted GUMCAD data to UKHSA, 93% of which submitted data aligned to the enhanced specification of GUMCAD. Given the gaps in reporting (missing data on sexual behaviour from some SHS in London, as well as online SHS), the first tranche of enhanced GUMCAD data on gender identity and recent sex partners were published as provisional data in July 2024 [25].

Of all the 4,610,410 attendances and consultations at SHS in England in 2023, gender identity was reported 96% of records, and data on whether this varied from the sex registered at birth was reported for 88% of these records. That year, transgender women, transgender men, and gender diverse (identifying as non-binary or in any other way) people each made up less than 1% of people accessing SHS in England (Figure 1a), with similar proportions among those diagnosed with gonorrhoea (Figure 1b), one of the most commonly reported STIs in England.

In 2023, data on the number of recent (prior 3 months) sex partners was reported for 28% (632,857/2,263,515) of face-to-face attendances in 2023, but these data were not reported for people being tested for STIs using online postal self-sampling kits. Where reported, the number of attendances and consultations, as well as the number of sexual health screens (tests for chlamydia, gonorrhoea, syphilis or HIV) were highest amongst SHS users reporting one recent sex partner, with the exception of GBMSM among whom it was highest in those reporting 2-4 recent sex partners (Figure 2a). The numbers of gonorrhoea and infectious syphilis diagnoses were also highest amongst most gender and sexual orientation groups reporting 1 recent sex partner; however, gonorrhoea and infectious syphilis were most frequently diagnosed in GBMSM reporting two or more recent sex partners (Figure 2b), consistent with the overall profile of clinic attendees in this group.

Discussion

Through iterative piloting, we identified the minimal sexual behaviour data that can be collected through routine STI surveillance. The provision of open access SHS through a publicly-funded healthcare system using a standardised set of clinical codes to report electronically has facilitated comprehensive reporting of STI surveillance in England, which has now been enhanced to include gender identity and sexual behaviours. UKHSA worked closely with key sexual health stakeholders to develop this enhanced specification which is now the dataset used for mandatory STI surveillance. This, in turn, facilitates the collection of more robust data to assess the uptake and inform the targeting of key interventions such as mpox vaccination among eligible individuals including gender minorities, as well as behavioural data to assess the use of condoms and the frequency of sexualised drug use or multiple partnerships among people attending SHS.

The experience of iteratively piloting the enhanced specification has emphasised the need to balance the granularity of behavioural data with the feasibility and acceptability of collecting and reporting them. A key lever for this enhancement of STI surveillance was the prioritisation of data on sexual behaviours that are routinely assessed during a sexual history at an SHS for inclusion in GUMCAD. Some variables such as self-reported past STI diagnoses or HIV testing were very poorly completed in the pilot and have been excluded from GUMCAD. However, to complement data from GUMCAD, UKHSA regularly runs community surveys to assess SHS access and need and, while these are based on convenience samples, they include data on people who do and those who do not access SHS [25]. UKHSA's collaborators also undertake high quality surveys such as Natsal to collect data from a nationally representative sample of the population [27], and the Gay Men's Sexual Health Survey, a biobehavioural survey of a convenience sample of GBMSM in large English cities [28]. During the pilots, multiple SHS using different EPR software systems were included to ensure that the enhanced specification of GUMCAD was software agnostic, and to facilitate rollout once the specification was approved.

England, in common with other high-income countries, has detected an increase in bacterial STIs since the end of lockdowns to control COVID-19 in 2021 [29]. England's high STI diagnosis rates compared to other countries [30] is in part an artefact of the comprehensive STI surveillance atop a national system for offering high standard and expert led sexual healthcare. Insights from this enhancement of GUMCAD to contextualise the occurrence of these infections will potentially be of wider benefit to other countries seeing similar patterns in their STI epidemiology. While the vast majority of SHS reported the enhanced specification of GUMCAD in 2023, there were gaps in reporting. Ongoing data quality improvement is underway through the use of a data quality scorecard for SHS, annual data quality meetings with regional UKHSA staff supporting SHS, and bespoke online and in-

person seminars to present the enhanced GUMCAD specification and to offer coding advice [31].

Despite the reporting gaps, the distribution of recent sex partners among people attending SHS by gender and sexual orientation reflected that of a large population-based survey, such that GBMSM were more likely to report multiple partnerships than heterosexuals [4,32]. The relatively low proportion of transgender and gender-diverse people attending SHS may be a reflection of the underlying distribution in the population [33] and the fact that they may access SHS less frequently than cisgender GBMSM (who are recommended to test for STIs quarterly if they are at risk of STIs [34]), as well as under-reporting of gender identity data in GUMCAD. The ability to report data on gender identity and whether this varies from the sex registered at birth though GUMCAD presents an opportunity to capture data on whether SHS users are cisgender, transgender or gender diverse then, with more complete reporting of these data, to use these data to more robustly assess inequalities in sexual health.

STI surveillance data, by their very nature, are highly sensitive so UKHSA has published supporting privacy information to explain why STI surveillance data are collected and the confidentiality controls in place to protect privacy [15]. Sexual health services in England operate with unique privacy safeguards and are covered by anonymous access provision in law [35]; in keeping with this, SHS report surveillance data pseudonymously such that individual service users cannot be identified from the information provided. STIs are not legally notifiable in England because the network of open access SHS conducts PN for STIs, and all SHS report depersonalised GUMCAD surveillance data [36,37].

These new enhanced data in GUMCAD are not without limitations, because they only represent people who access a SHS and because this reporting only commenced in most SHS in 2023, so it will take time to build up a time-series of data to contextualise STI trends. Further work is needed to minimise item non-response. Also, SHS are facing increased demands on the finite appointment time and testing resources, with a survey conducted by a leading community stakeholder in 2023 demonstrating that there were difficulties securing appointments [38]. It is therefore important for UKHSA to continue to support SHS to report GUMCAD by making it as easy as possible and making full use of the data to support understanding of STIs and their prevention.

With this enhancement to GUMCAD, UKHSA is now better equipped to understand the factors associated with STI trends, and the gaps in service provision which contribute to poorer control of STIs. Additionally, the ability to assess gender identity in GUMCAD facilitates more robust interpretation of STI surveillance data and a better understanding of the epidemiology of STIs among people who are transgender or gender diverse. The

enhanced GUMCAD specification also provides greater scope to use STI surveillance data to inform and evaluate public health interventions such as HIV-PrEP, or to plan for novel ones such as doxycycline post-exposure prophylaxis (doxyPEP) for syphilis prevention and 4CMenB vaccination for gonorrhoea. With triangulation against community survey and other data, there are more complete data to understand the sexual health and wellbeing of the population and to inform the commissioning of SHS and wider sexual health policy to reduce the incidence of STIs and STI-related harm.

Acknowledgements

The authors dedicate this article to the memory of Mr. David Stuart (Chemsex and HIV advocate at 56 Dean St, London – and former member of the Steering Group for the enhanced GUMCAD pilot) and Dr. Helen Wheeler (Clinical Lead and Sexual Health Consultant, and the lead for the enhanced GUMCAD pilot in Bristol).

The authors acknowledge Dr. Alan McOwan (56 Dean St, London); Mrs. Jacinta Ryan (Barnet, London); Dr. Gillian Dean (Claude Nicol Centre, Brighton); Dr. Ian Fairley and Ms. Corinna Dass (YorSexualHealth, York); and Mrs. Tracey Garratt (iCaSH Bedfordshire) for participating in the pilot, and the staff of all pilot services for their contributions. The authors acknowledge Ms. Martina Furegato (a former PHE employee who is now at Oracle Life Sciences) and Dr. Sarika Desai (a former PHE employee who is now at the World Health Organization) for their contributions to the pilot. The authors also thank Ms. Mandy Yung (UKHSA) for her support applying for approval for the enhanced GUMCAD specification.

Authors' contributions

HM wrote the first draft of the article and conducted the thematic analysis, while SJM and JW performed quantitative analyses. HM, MS, DP, AN, AS, JAC, CE, and GH were on the Steering Group for the pilots of the enhanced GUMCAD specification. All coauthors contributed to finalising the article before submission.

References

1. Savage E J, Marsh K, Duffell S, Ison C A, Zaman A, Hughes G. Rapid increase in gonorrhoea and syphilis diagnoses in England in 2011. Euro Surveill. 2012;17(29):pii=20224. https://doi.org/10.2807/ese.17.29.20224-en
2. Mohammed H, Blomquist P, Ogaz D, et al. 100 years of STIs in the UK: a review of national surveillance data. Sexually Transmitted Infections 2018;94:553-558.
3. Mohammed H, Mitchell H, Sile B, Duffell S, Nardone A, Hughes G. Increase in Sexually Transmitted Infections among Men Who Have Sex with Men, England, 2014. Emerg Infect Dis. 2016;22(1):88-91. https://doi.org/10.3201/eid2201.151331
4. Mercer, C.H., Prah, P., Field, N. et al. The health and well-being of men who have sex with men (MSM) in Britain: Evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). BMC Public Health 16, 525 (2016). https://doi.org/10.1186/s12889-016-3149-z
5. Ogaz D, Edney J, Phillips D, Mullen D, Reid D, Wilkie R, et al. (2024) Knowledge, uptake and intention to use antibiotic post-exposure prophylaxis and meningococcal B vaccine (4CMenB) for gonorrhoea among a large, online community sample of men and gender-diverse individuals who have sex with men in the UK. PLOS Glob Public Health 4(12): e0003807. https://doi.org/10.1371/journal.pgph.0003807
6. Fountain H, Migchelsen SJ, Charles H, Ram T, Fifer H, Mohammed H, et al. Rebound of Gonorrhea after Lifting of COVID-19 Preventive Measures, England. Emerg Infect Dis. 2024;30(2):329-332. https://doi.org/10.3201/eid3002.231148
7. Migchelsen SJ, Edney J, O'Brien N, El Hakim C, Narayanan P, Harb AK, et al. Sexually transmitted infections and screening for chlamydia in England, 2023. June 2024, UK Health Security Agency, London Available at https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2023-report. Accessed 26 February 2025.
8. British Association for Sexual Health and HIV. Standard for the Management of STIs. Available at https://www.bashh.org/resources/81/standards_for_the_management_of_stis/. Accessed 26 February 2025.
9. Wetten S, Mohammed H, Yung M, Mercer CH, Cassell JA, Hughes G. Diagnosis and treatment of chlamydia and gonorrhoea in general practice in England 2000–2011: a population-based study using data from the UK Clinical Practice Research Datalink. BMJ Open 2015;5:e007776. doi: 10.1136/bmjopen-2015-007776.

10. Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis. PLoS One 2021. //doi.org/10.1371/journal.pone.0260063.
11. Mohammed H, Sile B, Furegato M, Fifer H, Hughes G. British Journal of General Practice 2016; 66 (648): 352. DOI: https://doi.org/10.3399/bjgp16X686077.
12. British Association for Sexual Health and HIV. Love GUM – What is GUM? Available at https://lovegum.bashh.org/. Accessed 14 Mar 2025.
13. Savage E J, Mohammed H, Leong G, Duffell S, Hughes G. Improving surveillance of sexually transmitted infections using mandatory electronic clinical reporting: the genitourinary medicine clinic activity dataset, England, 2009 to 2013. Euro Surveill. 2014;19(48):pii=20981. https://doi.org/10.2807/1560-7917.ES2014.19.48.20981
14. Office for Health Improvement and Disparities and UK Health Security Agency. Integrated sexual health service specification 2023. Available at https://assets.publishing.service.gov.uk/media/6412fa41d3bf7f79d7b78f5d/Integrated-sexual-health-service-specification-2023.pdf. Accessed 26 February 2025.
15. UK Health Security Agency. Sexual Health and HIV Privacy Information. Available at: https://www.gov.uk/government/publications/ukhsa-sexual-health-and-hiv-privacy-information. Accessed 26 February 2025.
16. National Health Service. NHS Data Model and Dictionary. Available at https://www.datadictionary.nhs.uk/. Accessed 26 February 2025.
17. Office for National Statistics. Statistical Geographies. Available at https://www.ons.gov.uk/methodology/geography/ukgeographies/statisticalgeographies. Accessed 26 February 2025.
18. Bardsley M, Wayal S, Blomquist P, Mohammed H, Mercer CH, Hughes G. Improving our understanding of the disproportionate incidence of STIs in heterosexually-identifying people of Black Caribbean heritage: findings from a longitudinal study of sexual health clinic attendees in England. Sex Transm Infect. 2022; 98:23-31.
19. Brook G, Bacon L, Evans C, et al. 2013 UK national guideline for consultations requiring sexual history taking. Clinical Effectiveness Group British Association for Sexual Health and HIV. International Journal of STD & AIDS. 2014;25(6):391-404. doi:10.1177/0956462413512807
20. McClean H, Radcliffe K, Sullivan A, Ahmed-Jushuf I. 2012 BASHH statement on partner notification for sexually transmissible infections. International Journal of STD & AIDS. 2013;24(4):253-261. doi:10.1177/0956462412472804

21. UK Health Security Agency. GUMCAD: data specification and technical guidance. Available at https://www.gov.uk/government/publications/gumcad-data-specification-and-technical-guidance. Accessed 3 March 2025
22. Society of Sexual Health Advisers. About us. Available at https://ssha.info/about-2/. Accessed 14 Mar 2025.
23. Spence, T., Howarth, A., Reid, D. Sheringham J, Apea V, Crundwell D et al. How does online postal self-sampling (OPSS) shape access to testing for sexually transmitted infections (STIs)? A qualitative study of service users. BMC Public Health 24, 2339 (2024). https://doi.org/10.1186/s12889-024-19741-x
24. NHS England Digital. DCB0139: GUMCAD STI Surveillance System. Available at https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/dcb0139-gumcad-sti-surveillance-system. Accessed 26 February 2025.
25. UK Health Security Agency. STI annual data. Available at https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables. Accessed 3 Mar 2025
26. Brown JR, Reid D, Howarth AR, et al. Changes in STI and HIV testing and testing need among men who have sex with men during the UK's COVID-19 pandemic response. Sexually Transmitted Infections 2023;99:226-238.
27. Natsal study. Available at https://www.natsal.ac.uk/. Accessed 27 Feb 2024.
28. Ogaz D, Logan L, Curtis TJ, McDonagh L, Guerra L, Bradshaw D, et al. PrEP use and unmet PrEP-need among men who have sex with men in London prior to the implementation of a national PrEP programme, a cross-sectional study from June to August 2019. BMC Public Health. 2022 Jun 3;22(1):1105. doi: 10.1186/s12889-022-13425-0.
29. Nerlander L, Champezou L, Gomes Dias J, Aspelund G, Berlot L, Constantinou E et al. Sharp increase in gonorrhoea notifications among young people, EU/EEA, July 2022 to June 2023. Euro Surveill. 2024;29(10):pii=2400113. https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400113
30. World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030: report on progress and gaps 2024. Available at https://iris.who.int/bitstream/handle/10665/376814/9789240094925-eng.pdf. Accessed 26 February 2025.
31. UK Health Security Agency. Quality and Methodology Information for the sexually transmitted infections and National Chlamydia Screening Programme data release

for England. Available at https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/quality-and-methodology-information-and-development-plan-for-official-statistics-in-development-on-sexually-transmitted-infections. Accessed 26 February 2025

32. Sonnenberg P, Clifton C, Beddows S, Field N, Soldan K, Tanton C et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet, Volume 382, Issue 9907, 1795 - 1806
33. Office for National Statistics. Gender identity, England and Wales: Census 2021. Available at https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/genderidentity/bulletins/genderidentityenglandandwales/census2021. Accessed 14 Mar 2025.
34. Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, et al. 2016 United Kingdom national guideline on the sexual health care of men who have sex with men. Int J STD AIDS. 2018 Jan 1:956462417746897. doi: 10.1177/0956462417746897.
35. NHS Transformation Directorate. HIV and Sexually Transmitted Infections (STIs). Available at https://transform.england.nhs.uk/information-governance/guidance/hiv-and-sexually-transmitted-infections-stis/. Accessed 26 February 2025
36. Department of Health. Health Protection Legislation (England) Guidance 2010. Available at: https://webarchive.nationalarchives.gov.uk/ukgwa/20130105041349/http:/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_114510. Accessed 7 Jan 2025.
37. Mohammed H, Folkard K, Phillips M, Phillips D, Fifer H, Sinka K. Updates to the notifiable disease legislation in England to facilitate surveillance of selected STI-related complicationsSexually Transmitted Infections Published Online First: 29 March 2025. doi: 10.1136/sextrans-2025-056500
38. Terrence Higgins Trust. Mystery shopper: access to sexual health services. Available at https://www.tht.org.uk/about-us/what-we-do/our-campaigns/tackling-inequalities-sexual-health/mystery-shopper-access-sexual-health. Accessed 26 February 2025.

499 Table 1a – Variables included in the piloted GUMCAD Sexually Transmitted Infection Surveillance System, England (first pilot – 2013/14)

Sexual behaviour		
Heterosexual partnerships	*Men who have sex with men*	*Women who have sex with men*
Number of heterosexual sex partners in the last 3 months?	Number of MSM sex partners in the last 3 months?	Number of WSW sex partners in the last 3 months?
†How many of these were new sex partners (i.e. you have not had sex with them before)?	†How many of these were new sex partners (i.e. you have not had sex with them before)?	†How many of these were new sex partners (i.e. you have not had sex with them before)?
†How many of these new sex partners were encounters abroad (i.e. you did not have sex in the UK)?	†How many of these new sex partners were encounters abroad (i.e. you did not have sex in the UK)?	†How many of these new sex partners were encounters abroad (i.e. you did not have sex in the UK)?
†Were any of these encounters abroad with someone born in the: (please check all that apply) – UK, Western Europe, Eastern Europe, Sub-Saharan Africa, Caribbean, Other/Unknown Region	†Were any of these encounters abroad with someone born in the: (please check all that apply) – UK, Western Europe, Eastern Europe, Sub-Saharan Africa, Caribbean, Other/Unknown Region	†Were any of these encounters abroad with someone born in the: (please check all that apply) – UK, Western Europe, Eastern Europe, Sub-Saharan Africa, Caribbean, Other/Unknown Region
	†Of all the sex partners (in the last 3 months) how many did you have (receptive or insertive) anal sex with?	
	†How many anal sex partners did you have unprotected (receptive or insertive) anal sex with?	
	†How many unprotected anal sex partners were of a discordant or unknown HIV status?	
	†How many unprotected anal sex partners did you have receptive anal sex with?	

	†How many of these partners (you had unprotected receptive anal sex with) were living with HIV?	
	†How many of these partners (you had unprotected receptive anal sex with) were HIV negative?	
Sexual behaviour		
Did you/your partner use a condom the last time you had penetrative (vaginal or anal) sex?		
†Were you under the influence of alcohol (before or during sex) with any partner in the last 3 months?		
‡Have you used recreational drugs in the last 6 months?		
Were you under the influence of recreational drugs (before or during sex) with any partner in the last 3 months?		
‡Which drug did you take? (please check all that apply; responses : yes (injected/yes (not injected)/no) – Amphetamine/Speed, Cannabis, Cocaine, Crack, Crystal Meth/Methamphetamine, Ecstasy (E)/MDMA, GHB/GBL, Heroin, Solvents/Glue, Ketamine, Mephedrone (M-Cat), Methadone, Benzodiazepines (non-prescribed), Poppers, Other		
Previous STIs		
Have you ever attended another genitourinary medicine service – No, In the last year, In the last 1-5 years, Over 5 years ago		
†Are you living with HIV?		
†Are you living with Hepatitis C?		
New registrants only: Have you been diagnosed with an STI in the past year? If so (check all that apply) – chlamydia, gonorrhoea, herpes (genital), LGV, syphilis, warts (genital), other When did you last have an HIV test? – In the last year, In the last 1-5 years, Over 5 years ago		
Partner Notification		

Date of initial PN discussion
How many partners were reported during the relevant 'look-back interval'* for the STI(s) diagnosed?
How many of these partners were contactable?
How many of these partners were reported by the index patient as having attended a sexual health service (level 1, 2 or 3) within 4 weeks of the initial PN discussion?
How many of these partners were verified*** by a HCW as attending a sexual health service (level 1, 2 or 3) within 4 weeks of the initial PN discussion?

† - removed from the specification for the second pilot

‡ - amended in the specification for the second pilot

* Look-back interval (based on STI in keeping with guidance from the British Association for Sexual Health and HIV

** A partner is defined as contactable if the index patient is able and willing to either inform the partner of the risk of infection themself, or willing to pass on contact details to the healthcare work for provider referral.

*** 'Verified' means confirming contact attendance by checking records in your own service, or by contacting other services where contacts may have attended

511 Table 1b – Variables included in the piloted GUMCAD Sexually Transmitted Infection Surveillance System, England (second pilot – 2015/16)

Sexual behaviour		
Heterosexual partnerships	*Men who have sex with men*	*Women who have sex with men*
Number of heterosexual sex partners in the last 3 months?	Number of MSM sex partners in the last 3 months?	Number of WSW sex partners in the last 3 months?
How many of these were new sex partners (i.e. you haven't had sex with them before)?	How many sex partners did you have in the last 3 months?	How many of these were new sex partners (i.e. you haven't had sex with them before)?
	Have you had anal (receptive or insertive) sex with a known partner living with HIV in the last 3 months?	
	Have you had any condomless anal intercourse in the last 3 months?	
	Have you had any receptive condomless anal intercourse in the last 3 months?	
Sexual behaviour		
Was alcohol use assessed? If so, was alcohol use assessed as problematic?		
Have you used recreational drugs in the last 3 months?		
Which drug did you take? (please check box where applicable) – Amphetamine/Speed, Benzodiazepines (non-prescribed), Cannabis, Cocaine, Crack, Crystal Meth/Methamphetamine, Ecstasy (E)/MDMA, GHB/GBL, Heroin, Ketamine, Novel psychoactive substances, Mephedrone (M-Cat), Methadone, Poppers, Solvents/Glue, Other		
Did you inject any recreational drug in the last 3 months? If yes: Did you share equipment with anyone when injecting drugs?		
Were you under the influence of recreational drugs (before or during sex) the last time you had sexual intercourse?		
†Previous STIs		
†Have you ever attended another sexual health service?		

†New registrants only: Have you been diagnosed with an STI in the past year? If so – chlamydia, gonorrhoea, herpes (genital), LGV, non-specific genital infection, syphilis, warts (genital), other †When did you last have an HIV test? – In the last year, In the last 1-5 years, Over 5 years ago
Partner Notification
Date of initial PN discussion
How many partners were reported during the relevant 'look-back interval'* for the STI(s) diagnosed?
How many of these partners were contactable?
How many of these partners were reported by the index patient as having attended a sexual health service (level 1, 2 or 3) within 4 weeks of the initial PN discussion?
How many of these partners were verified*** by a HCW as attending a sexual health service (level 1, 2 or 3) within 4 weeks of the initial PN discussion?
†How many of these partners were encounters abroad (i.e. you did not have sex in the UK)?
†For people diagnosed with HIV or gonorrhoea: Were any of these encounters abroad with someone born in (select all that apply): Australasia, Caribbean, Eastern Europe, North America, South America, Southeast Asia, Sub-Saharan Africa, UK, Western Europe, Other

† - removed from the final GUMCAD specification

The current GUMCAD specification is published here: https://www.gov.uk/government/publications/gumcad-clinical-guidelines

* Look-back interval (based on STI in keeping with guidance from the British Association for Sexual Health and HIV

** A partner is defined as contactable if the index patient is able and willing to either inform the partner of the risk of infection themself, or willing to pass on contact details to the healthcare work for provider referral.

*** 'Verified' means confirming contact attendance by checking records in your own service, or by contacting other services where contacts may have attended

Figure 1a. Number of attendances at sexual health services and consultations at online sexual health services by gender identity, England, 2023.



Figure 1b. Number of gonorrhoea diagnoses at sexual health services by gender identity, England, 2023.



Data source: Routine sexual health services' submissions to the GUMCAD Sexually Transmitted Infection Surveillance System.

Note: Gender identity was reported by 91% (219/241) sexual health services in England in 2023, representing 88% of the overall number of attendances or consultations at sexual health services in 2023.

Cisgender people are those for whom their gender identity is the same as the sex registered at birth. Gender diverse is defined as identifying as non-binary or in any other way.

Figure 2a. Number of attendances at sexual health services (left) and sexual health screens (right) by the numbers of recent sex partners (last 3 months), by gender identity and sexual orientation group, England, 2023



Figure 2b. Number of diagnoses of gonorrhoea (left) and infectious syphilis (primary, secondary and early latent stages; right) by the numbers of recent sex partners (last 3 months), by gender and sexual orientation group, England, 2023



Different scales are used on the y-axes of each of the graphs above.

Data source: Routine sexual health services' submissions to the GUMCAD Sexually Transmitted Infection Surveillance System.

WSM – women who have sex with men; MSW – men who have sex with women; GBMSM – gay, bisexual and other men who have sex with men; WSW – women who have sex with women (exclusively). In this figure, 'women' refers to both cisgender and transgender women, and 'men' refers to both cisgender and transgender men.

Note: The number of recent sex partners was reported by 88% (206/235) of sexual health services (SHS) in England in 2023. Therefore, the graphs above only include data from the equivalent 88% of SHS - so the numbers of consultations, sexual health screens (tests for chlamydia, gonorrhoea, syphilis or HIV), gonorrhoea diagnosis and infectious syphilis diagnoses are lower than the overall total.